Additionally, F79 treatment induced synthetic lethality in BRCA1/2-mutated breast, pancreatic, and ovarian cancer cells and exerted synergistic effects with imatinib (approved for BCR-ABL1-positive leukemia) and ATRA (for PML-RAR-positive leukemia) [84]. The gene discussed is BRCA1; the disease is leukemia.